MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
Company Research
Source: GlobeNewswire
In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated with SLK, including ASDAS-CRP and SPARCC MRIaxSpA is a disease driven by inflammation leading to irreversible ossification (via osteoblast activity) and ultimately to irreversible restriction of mobility – objective PET/MRI imaging data further showed a significant reduction in inflammation and osteoblast activity deep in affected joints, already by week 12, suggesting potential for disease modification in axSpA for SLKAs a biomarker-controlled trial, S-OLARIS data showed SLK reduced the levels of key inflammatory mediators in axSpA, in peripheral blood and biopsy samples from patients – the safety profile of SLK was similar to other trials and no new signals were detectedMoonLake ended the f
Show less
Read more
Impact Snapshot
Event Time:
MLTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLTX alerts
High impacting MoonLake Immunotherapeutics - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MLTX
News
- MoonLake Immunotherapeutics (MLTX) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have a "sector perform" rating on the stock.MarketBeat
- Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update [Yahoo! Finance]Yahoo! Finance
- MoonLake Immunotherapeutics (MLTX) had its price target raised by HC Wainwright from $32.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- MoonLake Immunotherapeutics (MLTX) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at BTIG Research from $24.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
MLTX
Earnings
- 2/25/26 - Miss
MLTX
Sec Filings
- 2/25/26 - Form 10-K
- 2/23/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- MLTX's page on the SEC website